ALAS1 and anhaptoglobinemia: Givosiran, an siRNA molecule directed against hepatic ALAS1 mRNA, was approved by the FDA and the European Medicines Agency, following a 6-month randomized, double-blinded, placebo-controlled phase-3 study in AHP patients.